UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Journal of clinical oncology, 2021-02, Vol.39 (6), p.619-630

2021

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Clinical cancer research, 2019-01, Vol.25 (1), p.64-72

2019

Link zum Volltext

Verfügbarkeit prüfen

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

The lancet oncology, 2019-10, Vol.20 (10), p.1395-1408

2019

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Journal of clinical oncology, 2022-09, Vol.40 (25), p.JCO2102660-2933

2022

Link zum Volltext

Verfügbarkeit prüfen

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR‐Mutated Non–Small Cell Lung Cancer

Journal of clinical pharmacology, 2019-08, Vol.59 (8), p.1099-1109

2019

Link zum Volltext

Verfügbarkeit prüfen

The impact of next-generation sequencing on the DNA methylation–based translational cancer research

Translational research : the journal of laboratory and clinical medicine, 2016-03, Vol.169, p.1-18.e1

2016

Link zum Volltext

Verfügbarkeit prüfen

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

British journal of clinical pharmacology, 2018-06, Vol.84 (6), p.1156-1169

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

British journal of cancer, 2019-07, Vol.121 (2), p.131-138

2019

Link zum Volltext

Verfügbarkeit prüfen

Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study

Lung cancer (Amsterdam, Netherlands), 2015-12, Vol.90 (3), p.427-432

2015

Link zum Volltext

Verfügbarkeit prüfen

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

Clinical and translational medicine, 2021-07, Vol.11 (7), p.e491-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer

Clinical & translational oncology, 2023-04, Vol.25 (4), p.882-896

2023

Link zum Volltext

Verfügbarkeit prüfen

Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer

Clinical & translational oncology, 2023-04, Vol.25 (4), p.897-911

2023

Link zum Volltext

Verfügbarkeit prüfen

Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME)

Lung cancer (Amsterdam, Netherlands), 2012-12, Vol.78 (3), p.263-269

2012

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

The New England journal of medicine, 2018-12, Vol.379 (24), p.2342-2350

2018

Link zum Volltext

Verfügbarkeit prüfen

A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer

Clinical & translational oncology, 2011-05, Vol.13 (5), p.289-293

2011

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study

Lung cancer (Amsterdam, Netherlands), 2016-02, Vol.92, p.35-40

2016

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer

Current treatment options in oncology, 2021-10, Vol.22 (10), p.91-91, Article 91

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

Lung cancer (Amsterdam, Netherlands), 2011-12, Vol.74 (3), p.529-534

2011

Link zum Volltext

Verfügbarkeit prüfen

Adenoid Cystic Carcinoma of the Lung. A Case Report

Archivos de bronconeumología (English ed.), 2016-01, Vol.52 (1), p.50-50

2016

Link zum Volltext

Verfügbarkeit prüfen

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

PloS one, 2009-12, Vol.4 (12), p.e8199-e8199

2009

Link zum Volltext

Verfügbarkeit prüfen

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Translational lung cancer research, 2013-04, Vol.2 (2), p.142-151

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(62)
Life Sciences & Biomedicine
(60)
Humans
(55)
Oncology
(51)
Middle Aged
(34)
Male
(33)
Female
(32)
Aged
(28)
Lung Cancer
(28)
Lung Neoplasms - Drug Therapy
(25)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(24)
Adult
(22)
Chemotherapy
(19)
Aged, 80 And Over
(18)
Tumors
(18)
Carcinoma, Non-Small-Cell Lung - Pathology
(17)
Lung Neoplasms - Pathology
(17)
Pulmonary/respiratory
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(15)
Immunotherapy
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR‐Mutated Non–Small Cell Lung Cancer

The impact of next-generation sequencing on the DNA methylation–based translational cancer research

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer

Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer

Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME)

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer

Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

Adenoid Cystic Carcinoma of the Lung. A Case Report

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Suchergebnisse filtern